文献速递前列腺癌

磁共振成像与靶向融合活检用于前列腺癌早期检测的成本效益

Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
PubMed 文献 · BJU Int · 2018-03-08

该研究采用马尔可夫模型评估55至69岁PSA升高男性中MRI及靶向融合活检用于前列腺癌早期检测的成本效益。最佳策略为PI-RADS≥3行联合活检、PI-RADS<3不做活检,ICER为23 483美元/QALY,并使筛查活检次数减少15%。

要点

  • MRI阴性时不做活检优于标准活检,后者费用更高且QALYs更低。
  • 最佳策略为PI-RADS≥3行联合活检、PI-RADS<3不做活检。
  • 该策略ICER为23 483美元/QALY,筛查活检减少15%。

核心结论

  • MRI后行靶向MRI/超声融合活检可能是前列腺癌早期检测的一种成本效益方法。

研究设计与样本

  • 开发了前列腺癌发病与进展的马尔可夫模型,评估MRI筛查的健康与经济后果。
  • 患者从55岁至69岁接受PSA筛查,PSA>4 ng/mL者行MRI。

主要发现

  • MRI阴性时,标准活检比不做活检费用更高且QALYs更低。
  • 最佳筛查策略ICER为23 483美元/QALY,推荐PI-RADS≥3行联合活检、PI-RADS<3不做活检。
  • 该策略使筛查活检次数减少15%。

关键数值与推荐

  • PSA升高定义为>4 ng/mL。
  • MRI阳性者行靶向融合或联合(标准+靶向融合)活检,MRI阴性者行标准或不活检。
  • 阈值分析提示MRI敏感性和特异性与联合活检同时降低19个百分点时MRI仍具成本效益。

临床怎么用

  • 对PSA升高的55至69岁男性,可先行MRI,根据PI-RADS评分决定活检方式。
  • PI-RADS≥3推荐联合活检,PI-RADS<3可考虑不做活检以减少不必要活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine how best to use magnetic resonance imaging (MRI) and targeted MRI/ultrasonography fusion biopsy for early detection of prostate cancer (PCa) in men with elevated prostate-specific antigen (PSA) concentrations and whether it can be cost-effective. METHODS: A Markov model of PCa onset and progression was developed to estimate the health and economic consequences of PCa screening with MRI. Patients underwent PSA screening from ages 55 to 69 years. Patients with elevated PSA concentrations (>4 ng/mL) underwent MRI, followed by targeted fusion or combined (standard + targeted fusion) biopsy on positive MRI, and standard or no biopsy on negative MRI. Prostate Imaging Reporting and Data System (PI-RADS) score on MRI was used to determine biopsy decisions. Deaths averted, quality-adjusted life-years (QALYs), cost and incremental cost-effectiveness ratio (ICER) were estimated for each strategy. RESULTS: With a negative MRI, standard biopsy was more expensive and had lower QALYs than performing no biopsy. The optimum screening strategy (ICER $23 483/QALY) recommended combined biopsy for patients with PI-RADS score ≥3 and no biopsy for patients with PI-RADS score <3, and reduced the number of screening biopsies by 15%. Threshold analysis suggests MRI continues to be cost-effective when the sensitivity and specificity of MRI and combined biopsy are simultaneously reduced by 19 percentage points. CONCLUSIONS: Our analysis suggests MRI followed by targeted MRI/ultrasonography fusion biopsy can be a cost-effective approach to the early detection of PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Barnett CL, Davenport MS, Montgomery JS, et al. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018. PMID: 29388388. doi:10.1111/bju.14151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。